Inotiv (NOTV)
(Delayed Data from NSDQ)
$1.56 USD
+0.04 (2.63%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.55 -0.01 (-0.64%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.56 USD
+0.04 (2.63%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.55 -0.01 (-0.64%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Zacks News
Inotiv, Inc. (NOTV) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inotiv (NOTV) delivered earnings and revenue surprises of -122.22% and 14.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals (CRNX) delivered earnings and revenue surprises of -10.71% and 21.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Inotiv (NOTV) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Why Fast-paced Mover Inotiv (NOTV) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Inotiv (NOTV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Is Inotiv (NOTV) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Momentum in Inotiv, Inc. (NOTV) Should Keep going
by Zacks Equity Research
Inotiv, Inc. (NOTV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Inotiv, Inc. (NOTV) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Inotiv, Inc. (NOTV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Despite Fast-paced Momentum, Inotiv, Inc. (NOTV) Is Still a Bargain Stock
by Zacks Equity Research
Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Should Value Investors Buy Inotiv (NOTV) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's What Could Help Inotiv, Inc. (NOTV) Maintain Its Recent Price Strength
by Zacks Equity Research
Inotiv, Inc. (NOTV) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Inotiv, Inc. (NOTV) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Are Investors Undervaluing Inotiv (NOTV) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Inotiv, Inc. (NOTV) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -957.14% and 0.56%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
USANA Health Sciences (USNA) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
USANA Health (USNA) delivered earnings and revenue surprises of 67.31% and 6.96%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Inotiv, Inc. (NOTV) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Inotiv, Inc. (NOTV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Inotiv, Inc. (NOTV) Q3 Earnings Miss Estimates
by Zacks Equity Research
Inotiv, Inc. (NOTV) delivered earnings and revenue surprises of -73.08% and 6.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of -3.70% and 93.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ironwood (IRWD) delivered earnings and revenue surprises of 24% and 3.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adherex Technologies Inc. (FENC) delivered earnings and revenue surprises of -16.67% and 17.12%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 66.67% and 7.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Inotiv, Inc. (NOTV): Can Its 34.5% Jump Turn into More Strength?
by Zacks Equity Research
Inotiv, Inc. (NOTV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Are Options Traders Betting on a Big Move in Inotiv (NOTV) Stock?
by Zacks Equity Research
Investors need to pay close attention to Inotiv (NOTV) stock based on the movements in the options market lately.
Does Inotiv, Inc. (NOTV) Have the Potential to Rally 185.14% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 185.1% upside potential for Inotiv, Inc. (NOTV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 High Earnings Yield Gems for Successful Value Investing
by Rimmi Singhi
In the realm of value investing, the earnings yield metric serves as a powerful tool for identifying undervalued stocks with solid long-term growth potential. CCU, WNC, LOMA, JKS and NOTV are worth buying.